Sanofi launches new diabetes treatment insulin in India

作者:Gwendolyn 發表日期:2018-02-13 21:26:12

Drug firm Sanofi India today said it has launched diabetes treatment 'Toujeo' insulin in the country. The product, which is a next generation basal insulin, is a once-daily long-acting basal analog insulin that improves glycemic control in adults with type 1 and type 2 diabetes.

"The launch of Toujeo reaffirms our strong commitment of expanding Sanofi's portfolio and to drive better diabetes management in India," Sanofi India Managing Director N Rajaram said in a statement. Toujeo was first approved in 2015 in the United States and since then, it has been approved in over 65 countries.

It is a prescription drug and is available in the newly designed SoloSTAR pen. Low blood sugar, or hypoglycemia is a constant fear amongst people on insulin.

date = new Date(); date.setTime(date.getTime()+(1*24*60*60*1000)); $.cookie("dfp_cookie_article", "Y1", {expires: date,path:"/",domain: ""});

Toujeo effectively lowers blood glucose, while minimising the risk of hypoglycemia, Sanofi India said. It works by slowly releasing small amounts of insulin to provide continuous glucose-lowering activity that lasts beyond 24 hours, it added.

date = new Date(); date.setTime(date.getTime()+(1*24*60*60*1000)); $.cookie("dfp_cookie_article", "Y1", {expires: date,path:"/",domain: ""});Sanofi India shares were trading up 2.27 percent at Rs 4,828.75 on BSE.